Amica Mutual Insurance Co. Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Amica Mutual Insurance Co. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.6% during the fourth quarter, Holdings Channel reports. The firm owned 76,302 shares of the company’s stock after selling 8,095 shares during the quarter. Johnson & Johnson comprises about 1.3% of Amica Mutual Insurance Co.’s holdings, making the stock its 17th largest position. Amica Mutual Insurance Co.’s holdings in Johnson & Johnson were worth $11,960,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Massachusetts Wealth Management raised its position in Johnson & Johnson by 4.2% in the 3rd quarter. Massachusetts Wealth Management now owns 16,105 shares of the company’s stock valued at $2,508,000 after purchasing an additional 650 shares in the last quarter. U.S. Capital Wealth Advisors LLC raised its holdings in Johnson & Johnson by 4.5% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 135,863 shares of the company’s stock valued at $21,161,000 after acquiring an additional 5,877 shares in the last quarter. Slow Capital Inc. grew its holdings in Johnson & Johnson by 9.0% during the 3rd quarter. Slow Capital Inc. now owns 16,027 shares of the company’s stock worth $2,496,000 after acquiring an additional 1,318 shares in the last quarter. Trust Co. of Toledo NA OH increased its position in shares of Johnson & Johnson by 18.9% in the 3rd quarter. Trust Co. of Toledo NA OH now owns 36,528 shares of the company’s stock valued at $5,689,000 after purchasing an additional 5,805 shares during the last quarter. Finally, Evanson Asset Management LLC raised its holdings in shares of Johnson & Johnson by 0.8% in the 3rd quarter. Evanson Asset Management LLC now owns 13,901 shares of the company’s stock valued at $2,165,000 after purchasing an additional 113 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on JNJ shares. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Bank of America reduced their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, April 15th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $175.86.

Insider Transactions at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.4 %

JNJ opened at $149.27 on Friday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The business has a 50 day moving average price of $154.19 and a two-hundred day moving average price of $155.02. The company has a quick ratio of 0.91, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The company has a market cap of $359.25 billion, a PE ratio of 9.31, a P/E/G ratio of 2.46 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same quarter in the prior year, the business earned $2.68 earnings per share. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.32%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 29.68%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.